BioSpace News Archive

Dana-Farber Cancer Institute Joins the Parker Inst

Business

Janssen to Terminate Simeprevir License With Medivir, Effective June 2018

Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time.

December 10, 2017

·

1 min read

Drug Development

PharmaEssentia Announces Favorable Two-Year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ASH Annual Meeting 2017

Results reported last year at ASH 2016 showed that at 12 months, Ropeginterferon alfa-2b demonstrated non-inferiority to hydroxyurea in Complete Hematologic Response.

December 10, 2017

·

5 min read

Drug Development

Bioverativ Release: Study Shows Weekly Prophylactic Treatment With ELOCTATE Resulted in Bleed Protection and Target Joint Resolution in People With Hemophilia A

The analysis is being presented today in a poster session at the 59th Annual Meeting of the American Society of Hematology.

December 10, 2017

·

10 min read

Genetown

Acceleron Announces Updated Results From Ongoing Phase II Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology

Acceleron announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

December 10, 2017

·

9 min read

Genentech’s Frontline Alecensa Approved for Non-Sm

Drug Development

Genentech’s Lymphoma Drug Combo Wows in Mid-Stage Trial

These data led to FDA Breakthrough Therapy and EMA PRIME (PRIority MEdicines) designations.

December 10, 2017

·

10 min read

Drug Development

Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting

Kadmon announced additional positive findings from an ongoing Phase 2 clinical trial demonstrating that KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, was well tolerated and resulted in clinically meaningful responses in patients with chronic graft-versus-host disease (cGVHD).

December 10, 2017

·

6 min read

Pharm Country

Incyte Release: Four-Year Phase III Data Analysis Shows Durability of Response of Jakafi (ruxolitinib) in Patients With Polycythemia Vera

The pre-planned data analysis showed a durable primary response to Jakafi in patients with PV who are resistant to or intolerant of HU and the overall safety profile for Jakafi remained consistent with previously reported 80-week RESPONSE data.

December 10, 2017

·

12 min read

Genetown

Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach

Syros today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, show anti-tumor activity in in vitro and in vivo models of blood cancers.

December 10, 2017

·

6 min read

Drug Development

Primary Analysis Results From Novartis Pivotal JULIET Trial Show Kymriah (Tisagenlecleucel) Sustained Complete Responses at Six Months in Adults With r/r DLBCL, a Difficult-to-Treat Cancer

The data from this pivotal trial, led by researchers from the University of Penn, show an ORR of 53%, 42% 64%; p<0.0001, with 40% achieving a CR and 14% achieving a PR among 81 infused patients with three or more months of follow-up or earlier discontinuation.

December 10, 2017

·

17 min read

Moffitt Cancer Center Release: New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients

The new long-term results of the ZUMA-1 clinical trial reported measurable responses in 82 percent of patients and complete responses in 54 percent of patients.

December 10, 2017

·

3 min read